KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Revenue (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Revenue data on record, last reported at $196.9 million in Q4 2025.

  • For Q4 2025, Revenue rose 5.14% year-over-year to $196.9 million; the TTM value through Dec 2025 reached $726.4 million, up 3.63%, while the annual FY2025 figure was $726.4 million, 3.63% up from the prior year.
  • Revenue reached $196.9 million in Q4 2025 per PCRX's latest filing, up from $179.5 million in the prior quarter.
  • Across five years, Revenue topped out at $196.9 million in Q4 2025 and bottomed at $119.0 million in Q1 2021.
  • Average Revenue over 5 years is $165.4 million, with a median of $168.7 million recorded in 2024.
  • Peak YoY movement for Revenue: skyrocketed 79.58% in 2021, then decreased 2.11% in 2023.
  • A 5-year view of Revenue shows it stood at $159.2 million in 2021, then increased by 6.34% to $169.3 million in 2022, then grew by 7.07% to $181.2 million in 2023, then rose by 3.32% to $187.3 million in 2024, then rose by 5.14% to $196.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $196.9 million in Q4 2025, $179.5 million in Q3 2025, and $181.1 million in Q2 2025.